HRP20050679A2 - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents

Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Info

Publication number
HRP20050679A2
HRP20050679A2 HR20050679A HRP20050679A HRP20050679A2 HR P20050679 A2 HRP20050679 A2 HR P20050679A2 HR 20050679 A HR20050679 A HR 20050679A HR P20050679 A HRP20050679 A HR P20050679A HR P20050679 A2 HRP20050679 A2 HR P20050679A2
Authority
HR
Croatia
Prior art keywords
denotes
nr5r6
cycloalkyl
alkyl
alkenyl
Prior art date
Application number
HR20050679A
Other languages
Croatian (hr)
Inventor
Patek Marcel
Nair Anil
Hittinger Augustin
Nemecek Conception
Bond Daniel
Harlow Greg
Bouchard Herv
Mauger Jacques
Malleron Jean-Luc
Palermo Mark
Al-Obeidi Fahad
Faitg Thomas
Ruf Sven
Ritter Kurt
El-Ahmad Youssef
Lesuisse Dominique
Strobel Hartmut
Benard Didier
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20050679A2 publication Critical patent/HRP20050679A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Izum se odnosi na nove produkte koji imaju formulu (I), u kojoj: primjer označava 0 do 2, Radikal iR1 označavaju 0 ili NH; R2 i R3 označavaju vodik,alkil, alkenil, alkinil, cikloalkil, aril ili heteroaril, ili R2 i R3, zajedno s atomom ugljika na kojeg su vezani, tvore karbociklički ili heterociklički radikal, svi od navedenih radikala su po izboru supstituirani; A1 označava jednostruku vezu, alkil, alil ili propinil; Y i Y1 označavaju vodik, OCF3, S(O)nCF3, S(O)Alk, SO2CHF2, SO2CF2CF3, -O-CF2-CHF2, -O-CHF2, -O-CH2-CF3, SF5 i SO2NR5NR6, gdjesu R5 i R6 izabrani između vodika, alkil, alkenil, cikloalkil, cikloalkenil, heterocikloalkil, arili heteroaril, koji su po izboru supstituirani, ili R5 i R6 zajedno s N atomom na kojeg su vezani, tvore heterociklički radikal; A2 označava A1, CO i SO2; B2 označava heterociklički radikal koji je poizboru supstituiran s jednim ili više supstituenta koji su izabrani između mogućnosti od Y2; Y2 označava vodik, halogen, hidroksil, ciano, alkil, alkoksi, cikloalkil, heterocikloalkil, aril, heteroaril, -O-alkenil, -O-alkinil, -O-cikloalkil, S(O)n-alkil, - S(O)n-alkenil, - S(O)n-alkinil, - S(O)n-cikloalkil, -C00R13, NR5R6, CONR5R6, S(O)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, svi od navedenih radikala su po izboru supstituiran; i n označava cijeli broj između 0 i 2. Za uporabu kao medikamenata, ranije spomenuti produkti su u svim izomernim oblicima i soli od njih.The invention relates to novel products having the formula (I), in which: example denotes 0 to 2, Radical and R 1 denote 0 or NH; R 2 and R 3 denote hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heteroaryl, or R 2 and R 3, together with the carbon atom to which they are attached, form a carbocyclic or heterocyclic radical, all of which radicals are optionally substituted; A1 denotes a single bond, alkyl, allyl or propynyl; Y and Y1 denote hydrogen, OCF3, S (O) nCF3, S (O) Alk, SO2CHF2, SO2CF2CF3, -O-CF2-CHF2, -O-CHF2, -O-CH2-CF3, SF5 and SO2NR5NR6, where R5 and R 6 selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl heteroaryl, which are optionally substituted, or R 5 and R 6 together with the N atom to which they are attached form a heterocyclic radical; A2 denotes A1, CO and SO2; B2 denotes a heterocyclic radical optionally substituted with one or more substituents selected from the possibility of Y2; Y2 denotes hydrogen, halogen, hydroxyl, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-alkenyl, -O-alkynyl, -O-cycloalkyl, S (O) n-alkyl, - S (O) n-alkenyl, -S (O) n-alkynyl, -S (O) n-cycloalkyl, -C00R13, NR5R6, CONR5R6, S (O) n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13 , -NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6, -NR10-COOR13, all of these radicals are optionally substituted; and n denotes an integer between 0 and 2. For use as medicaments, the aforementioned products are in all isomeric forms and salts thereof.

HR20050679A 2003-01-31 2005-07-29 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors HRP20050679A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (en) 2003-01-31 2003-01-31 NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
PCT/FR2004/000188 WO2004070050A2 (en) 2003-01-31 2004-01-28 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Publications (1)

Publication Number Publication Date
HRP20050679A2 true HRP20050679A2 (en) 2006-12-31

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050679A HRP20050679A2 (en) 2003-01-31 2005-07-29 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1599464B1 (en)
JP (1) JP4604020B2 (en)
KR (1) KR20050098286A (en)
CN (1) CN1768054A (en)
AR (1) AR042936A1 (en)
AT (1) ATE482207T1 (en)
AU (1) AU2004209319A1 (en)
BR (1) BRPI0407091A (en)
CA (1) CA2513631A1 (en)
DE (1) DE602004029236D1 (en)
FR (1) FR2850652B1 (en)
HR (1) HRP20050679A2 (en)
MA (1) MA27651A1 (en)
ME (1) MEP22608A (en)
MX (1) MXPA05007407A (en)
NO (1) NO20054006L (en)
NZ (1) NZ541270A (en)
PE (1) PE20040808A1 (en)
PL (1) PL377811A1 (en)
RS (1) RS20050657A (en)
RU (1) RU2341523C2 (en)
TW (1) TW200505898A (en)
WO (1) WO2004070050A2 (en)
ZA (1) ZA200505934B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2384753T3 (en) * 2003-08-29 2016-09-30 Hydantoin derivatives as inhibitors of cellular necrosis
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE502298T1 (en) 2003-12-19 2011-04-15 Univ California METHODS AND MATERIALS FOR ASSESSING PROSTATE CANCER THERAPIES
AU2005232526B2 (en) 2004-02-24 2011-06-23 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101169832B1 (en) 2005-05-13 2012-07-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 Diarylhydantoin compounds
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896504B1 (en) * 2006-01-23 2012-07-13 Aventis Pharma Sa NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
FR2896503B1 (en) 2006-01-23 2012-07-13 Aventis Pharma Sa NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
EP3412290B1 (en) * 2006-03-27 2021-03-03 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CN101460467B (en) 2006-03-29 2012-09-19 加利福尼亚大学董事会 Diarylthiohydantoin compounds
AU2007283113A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008073365A1 (en) 2006-12-12 2008-06-19 Schering Corporation Aspartyl protease inhibitors
JP5535925B2 (en) 2007-10-26 2014-07-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Diarylhydantoin compounds as androgen receptor modulators
CA2772760A1 (en) 2008-12-23 2010-07-01 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EA028199B1 (en) * 2010-12-21 2017-10-31 Сайтек Текнолоджи Корп. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (en) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
WO2015108861A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3094326A4 (en) 2014-01-14 2017-07-26 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2970525A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
TWI726969B (en) 2016-01-11 2021-05-11 比利時商健生藥品公司 Substituted thiohydantoin derivatives as androgen receptor antagonists
CN107619388A (en) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 Heterocyclic compound as FGFR inhibitor
TWI712598B (en) * 2016-07-20 2020-12-11 瑞士商諾華公司 Aminopyridine derivatives and their use as selective alk-2 inhibitors
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
JP7005779B2 (en) * 2017-10-31 2022-02-10 ペレメッド カンパニー リミテッド Pharmaceutical composition for the prevention or treatment of acute myeloid leukemia or metastatic breast cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (en) * 1975-10-29 1977-05-27 Roussel Uclaf NEW SUBSTITUTES IMIDAZOLIDINES, METHOD OF PREPARATION, APPLICATION AS A MEDICINAL PRODUCT AND COMPOSITIONS CONTAINING THEM
DE4228717A1 (en) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidine derivatives
DE19540027A1 (en) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituted imidazolidine-2,4-dione compounds as active pharmaceutical ingredients
DE69811867T2 (en) * 1997-03-03 2003-11-20 Boehringer Ingelheim Pharma SMALL MOLECULES APPLICABLE IN TREATING INFLAMMATORY DISEASES
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
FR2796945B1 (en) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic NOVEL DERIVATIVES OF HYDANTOINS, THIOHYDANTOINS, PYRIMIDINEDIONES AND THIOXOPYRIMIDINONES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS
ES2284641T3 (en) * 2000-05-31 2007-11-16 Tanabe Seiyaku Co., Ltd. INHIBITORS OF CELLULAR ADHESION MEDIATED BY ALFA-L-BETA-2.
AU2003242249A1 (en) * 2002-05-16 2003-12-02 Bayer Cropscience Gmbh Pyridine carboxamide derivatives and their use as pesticides

Also Published As

Publication number Publication date
ZA200505934B (en) 2007-06-27
AU2004209319A1 (en) 2004-08-19
KR20050098286A (en) 2005-10-11
JP2006517569A (en) 2006-07-27
EP1599464B1 (en) 2010-09-22
TW200505898A (en) 2005-02-16
ATE482207T1 (en) 2010-10-15
JP4604020B2 (en) 2010-12-22
CN1768054A (en) 2006-05-03
EP1599464A2 (en) 2005-11-30
NO20054006D0 (en) 2005-08-29
WO2004070050A2 (en) 2004-08-19
RU2341523C2 (en) 2008-12-20
PL377811A1 (en) 2006-02-20
CA2513631A1 (en) 2004-08-19
DE602004029236D1 (en) 2010-11-04
BRPI0407091A (en) 2006-01-24
MXPA05007407A (en) 2005-09-12
AR042936A1 (en) 2005-07-06
WO2004070050A3 (en) 2005-02-17
NO20054006L (en) 2005-10-13
MEP22608A (en) 2010-06-10
PE20040808A1 (en) 2004-12-31
RU2005127335A (en) 2006-09-10
NZ541270A (en) 2008-11-28
FR2850652B1 (en) 2008-05-30
FR2850652A1 (en) 2004-08-06
MA27651A1 (en) 2005-12-01
RS20050657A (en) 2007-06-04

Similar Documents

Publication Publication Date Title
HRP20050679A2 (en) Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20082976L (en) Sulfur-containing cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors
NO20063780L (en) Process for the preparation of 2-aminithiazole-5-aromatic carboxamide as kinase inhibitors.
CO5580747A2 (en) N-ADAMANTILMETILO DERIVATIVES AND INTERMEDIARIES AS PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PREPARATION
NO20063028L (en) 6-substituted 2-quinolinones and 2-quinoxalinones as poly (adp-ribose) polymerase inhibitors
NO20054329L (en) Adamantan derivatives, processes for their preparation, and pharmaceutical compositions which include them
AR057979A1 (en) PIRAZOLPIRIMIDINAS AS INHIBITORS OF PROTEIN QUINASA. PHARMACEUTICAL COMPOSITIONS.
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AR053405A1 (en) SUBSTITUTED UREA DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOPATIAS
MXPA03010129A (en) N-aroyl cyclic amines.
AR050181A1 (en) UREA DERIVATIVES SUBSTITUTED CYCLES, ITS PREPARATION AND PHARMACEUTICAL USE AS QUINASA INHIBITORS
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
ES2333802T3 (en) NON-NUCLEIC INHIBITORS OF INVERSE TRANSCRIPT.
NO20051826L (en) Heterocyclic substituted piperazines for the treatment of schizophrenia
ATE533773T1 (en) PHOSPHORUS-CONTAINING HEPTAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS FLAME RETARDANTS
SE0202133D0 (en) Novel compounds
NO20082975L (en) Novel cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors
NO20061045L (en) imidazole
SE0303541D0 (en) New compounds
NO20062202L (en) Amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3,4-dihydro-2H-chromene-6-yl derivatives, processes and intermediates for their preparation, and drugs containing these compounds
MXPA04002495A (en) Imidazopyridine compounds as 5-ht4.
NO20060079L (en) 6- (1,1-Difluoroalkyl) -4-aminopicolinates and their use as herbicides
AR036812A1 (en) INHIBITORS OF THE 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES
FR2894578B1 (en) HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090127

Year of fee payment: 6

OBST Application withdrawn